HVEM antibody (Internal Region)
Quick Overview for HVEM antibody (Internal Region) (ABIN185517)
Target
See all HVEM (TNFRSF14) AntibodiesReactivity
Host
Clonality
Conjugate
Application
Grade
-
-
Binding Specificity
- Internal Region
-
Purpose
- HVEM / TR2
-
Sequence
- SVQRKRQEAE GE
-
Cross-Reactivity
- Human
-
Purification
- Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide.
-
Immunogen
- Peptide with sequence C-SVQRKRQEAEGE, from the internal region of the protein sequence according to NP_003811.2.
-
Isotype
- IgG
-
-
-
-
Application Notes
-
Immunohistochemistry: Paraffin embedded Human Kidney. Recommended concentration: 5 μg/mL.
Western Blot: Approx 30 kDa band observed in Human Thymus and Tonsil lysates (calculated MW of 30.4 kDa according to NP_003811.2). Recommended concentration: 0.03-0.1 μg/mL.
Peptide ELISA: antibody detection limit dilution 1:32000.
-
Restrictions
- For Research Use only
-
-
-
Format
- Liquid
-
Concentration
- 0.5 mg/mL
-
Buffer
- Supplied at 0.5 mg/mL in Tris saline, 0.02 % sodium azide, pH 7.3 with 0.5 % bovine serum albumin.
-
Preservative
- Sodium azide
-
Precaution of Use
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Handling Advice
- Minimize freezing and thawing.
-
Storage
- -20 °C
-
Storage Comment
- Aliquot and store at -20°C, with minimal freeze/thawing. A working aliquot may be refrigerated at 4°C for a few weeks and still remain viable.
-
-
- HVEM (TNFRSF14) (Tumor Necrosis Factor Receptor Superfamily, Member 14 (TNFRSF14))
-
Alternative Name
- TNFRSF14
-
Background
- TNFRSF14, HVEM, TR2, tumor necrosis factor receptor superfamily, member 14 (herpesvirus entry mediator), HGNC:11912, ATAR, HVEA, LIGHTR, CD40-like protein precursor, herpesvirus entry mediator, herpesvirus entry mediator A, tumor necrosis factor receptor
-
Gene ID
- 8764
-
NCBI Accession
- NP_003811
-
Pathways
- Production of Molecular Mediator of Immune Response, Cancer Immune Checkpoints
Target
-